IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.15
-0.01 (-0.46%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.16
Open2.16
Bid2.12 x 1000
Ask2.35 x 2200
Day's Range2.11 - 2.23
52 Week Range1.35 - 4.13
Volume43,171
Avg. Volume107,932
Market Cap44.891M
Beta1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • Associated Press9 days ago

    Imprimis: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 17 cents per share. The pharmaceutical and drug compounding company posted revenue of $8.9 million in the period. In the final minutes of trading on Tuesday, ...

  • Imprimis Pharmaceuticals Announces First Quarter 2018 Results
    PR Newswire9 days ago

    Imprimis Pharmaceuticals Announces First Quarter 2018 Results

    SAN DIEGO, May 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY) today reported financial results for the first quarter 2018. Imprimis Pharmaceuticals has retained ownership of 3.5 million shares of Eton Pharmaceuticals common stock and 3.5 million shares of Surface Pharmaceuticals common stock.  In addition, Imprimis owns mid-single digit royalty rights on all contributed drugs.  Imprimis retains royalty rights on two patent-pending sterile injectable drug candidates contributed to Eton, one targeting infantile spasms and the other targeting Peyronie's Disease.  Imprimis retains royalty rights on three patent-pending drug candidates contributed to Surface, two are topical eye drop drug candidates, the third is an oral capsule, all of which target certain ocular surface diseases.

  • Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners
    PR Newswire9 days ago

    Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

    SAN DIEGO, and PLEASANTON, Calif., May 15, 2018 /PRNewswire/ -- Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of up to approximately $20 million in a private placement of its Series A preferred stock.  Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates for up to five indications, as well as for general corporate purposes.

  • GlobeNewswire22 days ago

    Imprimis Pharmaceuticals to Host its First Quarter 2018 Financial Report Conference Call and Webcast on May 15, 2018 at 4:30 p.m. EDT

    Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release first quarter 2018 financial results after the close of trading on Tuesday, May 15, 2018.  The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8031 for domestic callers or (201) 689-8031 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website by clicking here.  A dial in replay of the call will be available until June 15, 2018.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 29148.  The webcast replay will be available until August 15, 2018.

  • Imprimis Pharmaceuticals Inc (NASDAQ:IMMY): Time For A Financial Health Check
    Simply Wall St.23 days ago

    Imprimis Pharmaceuticals Inc (NASDAQ:IMMY): Time For A Financial Health Check

    While small-cap stocks, such as Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) with its market cap of US$47.54M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • GlobeNewswire24 days ago

    Research Report Identifies Albany International, JBG SMITH Properties, Preferred Apartment Communities, National Western Life Group, Phibro Animal Health, and Imprimis Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, April 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?
    Simply Wall St.last month

    Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?

    Mark Baum took the helm as Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO and grew market cap to US$45.45M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
    PR Newswirelast month

    Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

    New combination topical drops and other cGMP (current good manufacturing practices) formulations will be showcased SAN DIEGO , April 10, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ...

  • Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
    PR Newswire2 months ago

    Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

    SAN DIEGO, March 27, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron) Melt® compounded formulation from the US Patent and Trademark office.  US Patent 9,918,993 B2 entitled "Pharmaceutical compositions for anesthesiological applications" was issued on March 20, 2018. Imprimis believes that beyond cataract surgery, there are likely more than 100 million annual procedures in the US ranging from dental, obstetric and gynecological, medical imaging procedures (such as MRIs and CAT scans), vasectomies, colonoscopies, dermatological, plastics procedures, orthopedic, otolaryngological, podiatry, emergency room, urology, and psychiatric that may benefit from an IV-free and opioid-free formulation.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Associated Press3 months ago

    Imprimis reports 4Q loss

    The San Diego-based company said it had a loss of 13 cents per share. The pharmaceutical and drug compounding company posted revenue of $7.3 million in the period. For the year, the company reported that ...

  • Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
    PR Newswire3 months ago

    Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

    SAN DIEGO , March 8, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017. Notable ...

  • ACCESSWIRE3 months ago

    Imprimis Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 4:30 PM Eastern ...

  • ACCESSWIRE3 months ago

    Wired News – Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications

    Stock Monitor: Akcea Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 08, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharma, Inc. (NASDAQ: IMMY ...

  • Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018
    PR Newswire3 months ago

    Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

    SAN DIEGO , March 7, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...

  • Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations
    PR Newswire3 months ago

    Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations

    SAN DIEGO, March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find and typically needed on an urgent basis.  The goal of this program is to provide high-quality compounded medications from an Imprimis FDA-inspected facility and ship it within 24-48 hours.  Imprimis intends to make this program available in all 50 US states. "Recent changes in ophthalmic compounding has made it such a challenge to access critical compounded medications, especially for infectious keratitis, where urgent care is essential," stated Marjan Farid, MD, Director of Cornea, Cataract, and Refractive Surgery, Vice-Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine.

  • Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?
    Simply Wall St.3 months ago

    Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?

    Measuring Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...

  • Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST
    PR Newswire3 months ago

    Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST

    SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial results after the close of trading on Thursday, March 8, 2018.  The company will host a conference call at 4:30 p.m. EST/1:30 p.m. PST on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8035 for domestic callers or (201) 689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A dial in replay of the call will be available until April 8, 2018.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 25720.  The webcast replay will be available until June 8, 2018.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 31, 2018 / U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow Jones ...

  • Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?
    Simply Wall St.4 months ago

    Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?

    I am going to take a deep dive into Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List
    PR Newswire4 months ago

    Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List

    SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that it is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide and the commercial products, Cosopt® and Cosopt® PF, were added to the FDA Drug Shortage List.

  • ACCESSWIRE4 months ago

    Blog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility

    LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ). If you want access to this report all you need ...

  • Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility
    PR Newswire4 months ago

    Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility

    SAN DIEGO, Jan. 24, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate. This new registration will further allow Imprimis to leverage its national compounding platform and its relationships with nearly 2,000 ophthalmology and optometric customers, including many of the largest ambulatory surgery centers in the US and numerous hospital systems, in order to provide patients and their healthcare professionals with affordable compounded formulations when they are clinically appropriate. By partnering with physicians to meet their patients' unmet needs, Imprimis continues to make progress in meeting its mission of bringing high quality innovative ophthalmic formulations to physicians and their patients.

  • What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength
    Simply Wall St.4 months ago

    What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength

    Investors are always looking for growth in small-cap stocks like Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), with a market cap of $33.27M. However, an important fact which most ignore is: how financiallyRead More...